QUARTERLY REPORT

Q2 2021 — Quarterly report

Q2 2021PDF · 30 pages134 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
È 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED June 30, 2021
or
‘ 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM 	TO
Commission File Number: 1-10864
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
Delaware 	41-1321939
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
UnitedHealth Group Center
9900 Bren Road East
Minnetonka, Minnesota 	55343
(Address of principal executive offices) 	(Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $.01 par value 	UNH 	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. 	Yes È 	No ‘
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). 	Yes È 	No ‘
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer 	È 	Accelerated filer ‘ 	Non-accelerated filer 	‘
Smaller reporting company 	‘ 	Emerging growth company ‘
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ‘
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 	Yes ‘ 	No È
As of July 30, 2021, there were 942,917,366 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.

-- 1 of 30 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. 	Financial Statements (unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1
Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020 . . . . . . . . . . . . . . . . . . . . 	1
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2021 and
2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2
Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30,
2021 and 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3
Condensed Consolidated Statements of Changes in Equity for the Three and Six Months Ended June 30, 2021
and 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 . . . . . . 	6
Notes to the Condensed Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7
1. 	Basis of Presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7
2. 	Investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8
3. 	Fair Value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10
4. 	Medical Costs Payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11
5. 	Short-Term Borrowings and Long-Term Debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11
6. 	Dividends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12
7. 	Commitments and Contingencies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12
8. 	Segment Financial Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	14
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . . . . . . . . . . . . . . 	16
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	25
Item 4. 	Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	25
Part II. Other Information
Item 1. 	Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26
Item 1A. 	Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26
Item 6. 	Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	27
Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	28

-- 2 of 30 --

PART I
ITEM 1. 	FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)
June 30,
2021
December 31,
2020
Assets
Current assets:
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	19,832 	$ 	16,921
Short-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,729 	2,860
Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	14,587 	12,870
Other current receivables, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12,630 	12,534
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,198 	4,076
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,940 	4,457
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	58,916 	53,718
Long-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	44,061 	41,242
Property, equipment and capitalized software, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,735 	8,626
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	75,827 	71,337
Other intangible assets, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,806 	10,856
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11,947 	11,510
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 210,292 	$ 197,289
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	25,131 	$ 	21,872
Accounts payable and accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	23,013 	22,495
Short-term borrowings and current maturities of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,868 	4,819
Unearned revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,365 	2,842
Other current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	22,180 	20,392
Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	76,557 	72,420
Long-term debt, less current maturities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	44,348 	38,648
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,641 	3,367
Other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12,425 	12,315
Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	136,971 	126,750
Commitments and contingencies (Note 7)
Redeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,299 	2,211
Equity:
Preferred stock, $0.001 par value—10 shares authorized; no shares issued or outstanding . . . . . . . . . . . . . . . . 	— 	—
Common stock, $0.01 par value—3,000 shares authorized; 943 and 946 issued and outstanding . . . . . . . . . . . 	10 	10
Additional paid-in capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	—
Retained earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	73,090 	69,295
Accumulated other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(4,086) 	(3,814)
Nonredeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,008 	2,837
Total equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	72,022 	68,328
Total liabilities, redeemable noncontrolling interests and equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 210,292 	$ 197,289
See Notes to the Condensed Consolidated Financial Statements
1

-- 3 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
June 30, Six Months Ended
June 30,
(in millions, except per share data) 	2021 	2020 	2021 	2020
Revenues:
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 56,233 $ 49,394 $ 111,719 $ 100,034
Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,433 	8,247 	16,773 	16,678
Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,099 	4,156 	12,017 	9,141
Investment and other income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	556 	341 	1,008 	706
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	71,321 	62,138 	141,517 	126,559
Operating costs:
Medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	46,546 	34,678 	91,450 	75,678
Operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,359 	10,001 	20,582 	20,016
Cost of products sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,660 	7,501 	15,232 	15,188
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	778 	717 	1,536 	1,440
Total operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	65,343 	52,897 	128,800 	112,322
Earnings from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,978 	9,241 	12,717 	14,237
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(410) 	(430) 	(807) 	(867)
Earnings before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,568 	8,811 	11,910 	13,370
Provision for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,196) 	(2,115) 	(2,560) 	(3,209)
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,372 	6,696 	9,350 	10,161
Earnings attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(106) 	(59) 	(222) 	(142)
Net earnings attributable to UnitedHealth Group common shareholders . . . . . . . . . . . . . . . . . . $ 4,266 $ 6,637 $ 	9,128 $ 10,019
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 	4.52 $ 	6.99 $ 	9.66 $ 	10.56
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 	4.46 $ 	6.91 $ 	9.55 $ 	10.43
Basic weighted-average number of common shares outstanding . . . . . . . . . . . . . . . . . . . . . . . . . 	944 	949 	945 	949
Dilutive effect of common share equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12 	11 	11 	12
Diluted weighted-average number of common shares outstanding . . . . . . . . . . . . . . . . . . . . . . . . 	956 	960 	956 	961
Anti-dilutive shares excluded from the calculation of dilutive effect of common share
equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1 	11 	2 	11
See Notes to the Condensed Consolidated Financial Statements
2

-- 4 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
June 30, Six Months Ended
June 30,
(in millions) 	2021 	2020 	2021 	2020
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	4,372 	$ 	6,696 	$ 	9,350 	$ 10,161
Other comprehensive income (loss):
Gross unrealized gains (losses) on investment securities during the period . . . . . . 	251 	1,120 	(513) 	771
Income tax effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(58) 	(257) 	116 	(177)
Total unrealized gains (losses), net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	193 	863 	(397) 	594
Gross reclassification adjustment for net realized gains included in net
earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(9) 	(11) 	(16) 	(29)
Income tax effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2 	3 	4 	7
Total reclassification adjustment, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . 	(7) 	(8) 	(12) 	(22)
Total foreign currency translation gains (losses) . . . . . . . . . . . . . . . . . . . . . . . . . . . 	554 	(45) 	137 	(1,544)
Other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	740 	810 	(272) 	(972)
Comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,112 	7,506 	9,078 	9,189
Comprehensive income attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . 	(106) 	(59) 	(222) 	(142)
Comprehensive income attributable to UnitedHealth Group common shareholders . . 	$ 	5,006 	$ 	7,447 	$ 	8,856 	$ 	9,047
See Notes to the Condensed Consolidated Financial Statements
3

-- 5 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Additional
Paid-In
Capital Retained
Earnings
Accumulated Other Comprehensive
Income (Loss)
Nonredeemable
Noncontrolling
Interests Total
Equity
Three months ended June 30,
(in millions)
Common Stock 	Net Unrealized Gains
on Investments
Foreign
Currency
Translation
(Losses)
Gains	Shares Amount
Balance at March 31, 2021 . . . . . . . . 	944 $ 	10 $ 	— $ 	71,220 $ 	741 $ 	(5,567) $ 	2,909 $ 69,313
Net earnings . . . . . . . . . . . . . . . . . . . 	4,266 	88 	4,354
Other comprehensive income . . . . . . 	186 	554 	740
Issuances of common stock, and
related tax effects . . . . . . . . . . . . . 	2 	— 	292 	292
Share-based compensation . . . . . . . . 	158 	158
Common share repurchases . . . . . . . 	(3) 	— 	(221) 	(1,029) 	(1,250)
Cash dividends paid on common
shares ($1.45 per share) . . . . . . . . 	(1,367) 	(1,367)
Redeemable noncontrolling interests
fair value and other
adjustments . . . . . . . . . . . . . . . . . . 	(229) 	— 	(229)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests . . . . . . . . . . . . . . . . . . . . . 	85 	85
Distribution to nonredeemable
noncontrolling interests . . . . . . . . . 	(74) 	(74)
Balance at June 30, 2021 . . . . . . . . . 	943 $ 	10 $ 	— $ 	73,090 $ 	927 $ 	(5,013) $ 	3,008 $ 72,022
Balance at March 31, 2020 . . . . . . . . 	947 $ 	10 $ 	— $ 	62,327 $ 	306 $ 	(5,666) $ 	2,886 $ 59,863
Net earnings . . . . . . . . . . . . . . . . . . . 	6,637 	38 	6,675
Other comprehensive income
(loss) . . . . . . . . . . . . . . . . . . . . . . . 	855 	(45) 	810
Issuances of common stock, and
related tax effects . . . . . . . . . . . . . 	3 	— 	287 	287
Share-based compensation . . . . . . . . 	144 	144
Common share repurchases . . . . . . . 	— 	— 	— 	— 	—
Cash dividends paid on common
shares ($1.25 per share) . . . . . . . . 	(1,188) 	(1,188)
Redeemable noncontrolling interests
fair value and other
adjustments . . . . . . . . . . . . . . . . . . 	(43) 	(43)
Distribution to nonredeemable
noncontrolling interests . . . . . . . . . 	(33) 	(33)
Balance at June 30, 2020 . . . . . . . . . 	950 $ 	10 $ 	388 $ 	67,776 $ 	1,161 $ 	(5,711) $ 	2,891 $ 66,515
See Notes to the Condensed Consolidated Financial Statements
4

-- 6 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common Stock 	Additional
Paid-In
Capital Retained
Earnings
Accumulated Other Comprehensive
Income (Loss)
Nonredeemable
Noncontrolling
Interests Total
Equity
Six months ended June 30,
(in millions)
Net Unrealized Gains
(Losses) on
Investments
Foreign
Currency
Translation
(Losses)
Gains	Shares Amount
Balance at January 1, 2021 . . . . . . . . . 	946 $ 	10 $ 	— $ 	69,295 $ 	1,336 $ 	(5,150) $ 	2,837 $68,328
Net earnings . . . . . . . . . . . . . . . . . . . . 	9,128 	168 	9,296
Other comprehensive (loss)
income . . . . . . . . . . . . . . . . . . . . . . . 	(409) 	137 	(272)
Issuances of common stock, and
related tax effects . . . . . . . . . . . . . . 	5 	— 	548 	548
Share-based compensation . . . . . . . . . 	400 	400
Common share repurchases . . . . . . . . 	(8) 	— 	(221) 	(2,679) 	(2,900)
Cash dividends paid on common
shares ($2.70 per share) . . . . . . . . . 	(2,548) 	(2,548)
Redeemable noncontrolling interests
fair value and other adjustments . . . 	(727) 	(106) 	(833)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests . . . . . . . . . . . . . . . . . . . . . . 	151 	151
Distribution to nonredeemable
noncontrolling interests . . . . . . . . . . 	(148) 	(148)
Balance at June 30, 2021 . . . . . . . . . . 	943 $ 	10 $ 	— $ 	73,090 $ 	927 $ 	(5,013) $ 	3,008 $72,022
Balance at January 1, 2020 . . . . . . . . . 	948 $ 	9 $ 	7 $ 	61,178 $ 	589 $ 	(4,167) $ 	2,820 $60,436
Adjustment to Adopt ASU
2016-13 . . . . . . . . . . . . . . . . . . . . . . 	(28) 	(28)
Net earnings . . . . . . . . . . . . . . . . . . . . 	10,019 	97 	10,116
Other comprehensive income
(loss) . . . . . . . . . . . . . . . . . . . . . . . . 	572 	(1,544) 	(972)
Issuances of common stock, and
related tax effects . . . . . . . . . . . . . . 	8 	1 	607 	608
Share-based compensation . . . . . . . . . 	378 	378
Common share repurchases . . . . . . . . 	(6) 	— 	(510) 	(1,181) 	(1,691)
Cash dividends paid on common
shares ($2.33 per share) . . . . . . . . . 	(2,212) 	(2,212)
Redeemable noncontrolling interests
fair value and other adjustments . . . 	(94) 	(94)
Acquisitions and other adjustments of
nonredeemable noncontrolling
interests . . . . . . . . . . . . . . . . . . . . . . 	50 	50
Distribution to nonredeemable
noncontrolling interests . . . . . . . . . . 	(76) 	(76)
Balance at June 30, 2020 . . . . . . . . . . 	950 $ 	10 $ 	388 $ 	67,776 $ 	1,161 $ 	(5,711) $ 	2,891 $66,515
See Notes to the Condensed Consolidated Financial Statements
5

-- 7 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Six Months Ended
June 30,
(in millions) 	2021 	2020
Operating activities
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 9,350 	$ 10,161
Noncash items:
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,536 	1,440
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	327 	114
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	426 	388
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(214) 	124
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,218) 	(439)
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,523) 	(3,784)
Medical costs payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,086 	(2,353)
Accounts payable and other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	298 	7,591
Unearned revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(523) 	(296)
Cash flows from operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11,545 	12,946
Investing activities
Purchases of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(8,847) 	(6,412)
Sales of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,408 	3,548
Maturities of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,650 	3,437
Cash paid for acquisitions, net of cash assumed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(4,642) 	(3,952)
Purchases of property, equipment and capitalized software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,130) 	(920)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(648) 	(186)
Cash flows used for investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(9,209) 	(4,485)
Financing activities
Common share repurchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,900) 	(1,691)
Cash dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,548) 	(2,212)
Proceeds from common stock issuances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	764 	870
Repayments of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,900) 	—
(Repayments of) proceeds from short-term borrowings, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(176) 	351
Proceeds from issuance of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,934 	4,864
Customer funds administered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,395 	1,263
Purchases of redeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,338) 	—
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(662) 	(421)
Cash flows from financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	569 	3,024
Effect of exchange rate changes on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6 	(143)
Increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,911 	11,342
Cash and cash equivalents, beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	16,921 	10,985
Cash and cash equivalents, end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 19,832 	$ 22,327
See Notes to the Condensed Consolidated Financial Statements
6

-- 8 of 30 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. 	Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is
a diversified health care company with a mission to help people live healthier lives and help make the health system work better
for everyone. Our two complementary business platforms—Optum and UnitedHealthcare—are driven by this unified mission
and vision to improve health care access, affordability, experiences and outcomes for the individuals and organizations we are
privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted
Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end
condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures
required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the
Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual
audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read
together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements” in the
Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC (2020 10-K). The
accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the
interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and
judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill.
Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters
that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in
earnings in the period in which the estimate is adjusted.
7

-- 9 of 30 --

2. 	Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
June 30, 2021
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3,526 	$ 	88 	$ 	(17) 	$ 	3,597
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,044 	386 	(7) 	7,423
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	21,116 	628 	(57) 	21,687
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,596 	167 	(30) 	6,733
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,623 	72 	(10) 	2,685
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	40,905 	1,341 	(121) 	42,125
Debt securities—held-to-maturity:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	412 	4 	— 	416
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	30 	2 	— 	32
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	148 	— 	(1) 	147
Total debt securities—held-to-maturity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	590 	6 	(1) 	595
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 41,495 	$ 1,347 	$ (122) 	$ 42,720
December 31, 2020
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3,335 	$ 	133 	$ 	(3) 	$ 	3,465
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,893 	435 	— 	7,328
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	18,886 	863 	(12) 	19,737
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,849 	245 	(3) 	7,091
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,116 	95 	(4) 	2,207
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	38,079 	1,771 	(22) 	39,828
Debt securities—held-to-maturity:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	420 	6 	— 	426
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	31 	2 	— 	33
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	187 	1 	— 	188
Total debt securities—held-to-maturity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	638 	9 	— 	647
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 38,717 	$ 1,780 	$ 	(22) 	$ 40,475
The Company held $2.8 billion and $2.3 billion of equity securities as of June 30, 2021 and December 31, 2020, respectively.
The Company’s investments in equity securities primarily consist of employee savings plan related investments, shares of
Brazilian real denominated fixed-income funds with readily determinable fair values and other venture investments.
Additionally, the Company’s investments included $1.3 billion of equity method investments in operating businesses in the
health care sector as of June 30, 2021 and December 31, 2020. The allowance for credit losses on held-to-maturity securities at
June 30, 2021 and December 31, 2020 was not material.
8

-- 10 of 30 --

The amortized cost and fair value of debt securities as of June 30, 2021, by contractual maturity, were as follows:
Available-for-Sale 	Held-to-Maturity
(in millions) Amortized
Cost Fair
Value Amortized
Cost Fair
Value
Due in one year or less . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	2,808 	$ 	2,822 	$ 	309 	$ 	310
Due after one year through five years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	13,088 	13,460 	231 	233
Due after five years through ten years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11,550 	12,000 	28 	29
Due after ten years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,240 	4,425 	22 	23
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,596 	6,733 	— 	—
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,623 	2,685 	— 	—
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	40,905 	$ 	42,125 	$ 	590 	$ 	595
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that
individual securities have been in a continuous unrealized loss position were as follows:
Less Than 12 Months 12 Months or Greater 	Total
(in millions) Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses
June 30, 2021
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . . . . . . $ 	1,201 $ 	(17) $ 	— 	$ 	— 	$ 	1,201 $ 	(17)
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	777 	(7) 	— 	— 	777 	(7)
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,679 	(56) 	229 	(1) 	4,908 	(57)
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . 	2,668 	(30) 	— 	— 	2,668 	(30)
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . 	713 	(8) 	42 	(2) 	755 	(10)
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 	10,038 $ 	(118) $ 	271 	$ 	(3) 	$ 	10,309 $ 	(121)
December 31, 2020
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . . . . . . $ 	346 $ 	(3) $ 	— 	$ 	— 	$ 	346 $ 	(3)
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,273 	(9) 	456 	(3) 	1,729 	(12)
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . 	601 	(3) 	— 	— 	601 	(3)
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . 	195 	(1) 	93 	(3) 	288 	(4)
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 	2,415 $ 	(16) $ 	549 	$ 	(6) 	$ 	2,964 $ 	(22)
The Company’s unrealized losses from debt securities as of June 30, 2021 were generated from approximately 6,500 positions
out of a total of 38,000 positions. The Company believes that it will collect the timely principal and interest due on its debt
securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate
increases and not by unfavorable changes in the credit quality associated with these securities that impacted our assessment on
collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for
any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the
expected cash flows, the underlying credit quality and credit ratings of the issuers noting no significant credit deterioration since
purchase. As of June 30, 2021, the Company did not have the intent to sell any of the available-for-sale debt securities in an
unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on
available-for-sale debt securities at June 30, 2021 and December 31, 2020 was not material.
9

-- 11 of 30 --

3. 	Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values
disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of
three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy
classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements in Part II,
Item 8, “Financial Statements” in the 2020 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair
value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
June 30, 2021
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	19,703 	$ 	129 	$ 	— 	$ 	19,832
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,379 	218 	— 	3,597
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	7,423 	— 	7,423
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	40 	21,416 	231 	21,687
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	6,733 	— 	6,733
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	2,685 	— 	2,685
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,419 	38,475 	231 	42,125
Equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,917 	20 	— 	1,937
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,803 	2,292 	103 	4,198
Total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	26,842 	$ 	40,916 	$ 	334 	$ 	68,092
Percentage of total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	39% 	60% 	1% 	100%
December 31, 2020
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	16,841 	$ 	80 	$ 	— 	$ 	16,921
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,241 	224 	— 	3,465
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	7,328 	— 	7,328
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	25 	19,424 	288 	19,737
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	7,091 	— 	7,091
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	2,207 	— 	2,207
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,266 	36,274 	288 	39,828
Equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,795 	33 	— 	1,828
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,774 	2,250 	52 	4,076
Total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	23,676 	$ 	38,637 	$ 	340 	$ 	62,653
Percentage of total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	38% 	61% 	1% 	100%
There were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2021 or 2020.
10

-- 12 of 30 --

The following table presents a summary of fair value measurements by level and carrying values for certain financial
instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
June 30, 2021
Debt securities—held-to-maturity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	494 	$ 	93 	$ 	8 	$ 	595 	$ 	590
Long-term debt and other financing obligations . . . . . . . . . . . . . . . . . . . . . . . 	$ 	— 	$ 54,023 	$ 	— 	$ 54,023 	$ 47,091
December 31, 2020
Debt securities—held-to-maturity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	466 	$ 	108 	$ 	73 	$ 	647 	$ 	638
Long-term debt and other financing obligations . . . . . . . . . . . . . . . . . . . . . . . 	$ 	— 	$ 51,254 	$ 	— 	$ 51,254 	$ 42,171
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are
subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were
no significant fair value adjustments for these assets and liabilities recorded during either the six months ended June 30, 2021 or
2020.
4. 	Medical Costs Payable
The following table shows the components of the change in medical costs payable for the six months ended June 30:
(in millions) 	2021 	2020
Medical costs payable, beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 21,872 	$ 21,690
Acquisitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	46 	41
Reported medical costs:
Current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	92,570 	76,338
Prior years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,120) 	(660)
Total reported medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	91,450 	75,678
Medical payments:
Payments for current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(69,808) 	(59,482)
Payments for prior years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(18,429) 	(18,727)
Total medical payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(88,237) 	(78,209)
Medical costs payable, end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 25,131 	$ 19,200
For the six months ended June 30, 2021 and June 30, 2020, prior years medical cost reserve development was primarily driven
by lower than expected health system utilization. Medical costs payable included reserves for claims incurred by insured
customers but not yet reported to the Company of $16.9 billion and $14.8 billion at June 30, 2021 and December 31, 2020,
respectively.
5. 	Short-Term Borrowings and Long-Term Debt
In May 2021, the Company issued $7.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages) Par
Value
0.550% notes due May 2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$1,000
1.150% notes due May 2026 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,000
2.300% notes due May 2031 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,500
3.050% notes due May 2041 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,500
3.250% notes due May 2051 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,000
11

-- 13 of 30 --

For more information on the Company’s short-term borrowings, debt covenants and long-term debt see Note 8 of Notes to the
Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the 2020 10-K.
6. 	Dividends
In June 2021, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual
rate of $5.80 compared to $5.00 per share, which the Company had paid since June 2020. Declaration and payment of future
quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.
The following table provides details of the Company’s 2021 dividend payments:
Payment Date 	Amount per Share 	Total Amount Paid
(in millions)
March 23 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	1.25 	$ 	1,181
June 29 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	1.45 	$ 	1,367
7. 	Commitments and Contingencies
Pending Acquisitions
The Company has entered into agreements to purchase companies in the health care sector, most notably Change Healthcare
(NASDAQ: CHNG), subject to regulatory approvals and other customary closing conditions. The total anticipated capital
required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately $9 billion.
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory
inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers
and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and
other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract
claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of
costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where
the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present
novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the
early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to
estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may
be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These
include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services
(CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the
Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade
Commission, U.S. Congressional committees, the U.S. Department of Justice, the SEC, the Internal Revenue Service, the U.S.
Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense
Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to
investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S.
governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for,
among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has
12

-- 14 of 30 --

selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices
of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to
payments made to the Company’s health plans.
On February 14, 2017, the Department of Justice (DOJ) announced its decision to pursue certain claims within a lawsuit initially
asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was
unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False
Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018,
DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary
judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the
Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this
matter given its procedural status.
13

-- 15 of 30 --

8. 	Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. For more
information on the Company’s segments see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial
Statements in Part II, Item 8, “Financial Statements” in the 2020 10-K.
The following tables present reportable segment financial information:
Optum
(in millions) 	UnitedHealthcare OptumHealth OptumInsight OptumRx Optum
Eliminations Optum Corporate and
Eliminations Consolidated
Three Months Ended June 30, 2021
Revenues—unaffiliated
customers:
Premiums . . . . . . . . . . . . . . . $ 	52,858 	$ 	3,375 	$ 	— 	$ 	— 	$ 	— $ 3,375 	$ 	— 	$ 	56,233
Products . . . . . . . . . . . . . . . . 	— 	9 	33 	8,391 	— 	8,433 	— 	8,433
Services . . . . . . . . . . . . . . . . 	2,440 	2,461 	930 	268 	— 	3,659 	— 	6,099
Total revenues—unaffiliated
customers . . . . . . . . . . . . . . . . . 	55,298 	5,845 	963 	8,659 	— 	15,467 	— 	70,765
Total revenues—affiliated
customers . . . . . . . . . . . . . . . . . 	— 	7,221 	1,921 	13,792 	(478) 	22,456 	(22,456) 	—
Investment and other income . . . . 	176 	234 	73 	73 	— 	380 	— 	556
Total revenues . . . . . . . . . . . . . . . $ 	55,474 	$ 	13,300 	$ 	2,957 	$ 22,524 	$ 	(478) $ 38,303 	$ 	(22,456) 	$ 	71,321
Earnings from operations . . . . . . $ 	3,095 	$ 	1,128 	$ 	762 	$ 	993 	$ 	— $ 2,883 	$ 	— 	$ 	5,978
Interest expense . . . . . . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(410) 	(410)
Earnings before income taxes . . . $ 	3,095 	$ 	1,128 	$ 	762 	$ 	993 	$ 	— $ 2,883 	$ 	(410) 	$ 	5,568
Three Months Ended June 30, 2020
Revenues—unaffiliated
customers:
Premiums . . . . . . . . . . . . . . . $ 	47,039 	$ 	2,355 	$ 	— 	$ 	— 	$ 	— $ 2,355 	$ 	— 	$ 	49,394
Products . . . . . . . . . . . . . . . . 	— 	7 	27 	8,213 	— 	8,247 	— 	8,247
Services . . . . . . . . . . . . . . . . 	1,895 	1,225 	764 	272 	— 	2,261 	— 	4,156
Total revenues—unaffiliated
customers . . . . . . . . . . . . . . . . . 	48,934 	3,587 	791 	8,485 	— 	12,863 	— 	61,797
Total revenues—affiliated
customers . . . . . . . . . . . . . . . . . 	— 	5,423 	1,823 	12,865 	(447) 	19,664 	(19,664) 	—
Investment and other income . . . . 	173 	129 	18 	21 	— 	168 	— 	341
Total revenues . . . . . . . . . . . . . . . $ 	49,107 	$ 	9,139 	$ 	2,632 	$ 21,371 	$ 	(447) $ 32,695 	$ 	(19,664) 	$ 	62,138
Earnings from operations . . . . . . $ 	7,007 	$ 	841 	$ 	561 	$ 	832 	$ 	— $ 2,234 	$ 	— 	$ 	9,241
Interest expense . . . . . . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(430) 	(430)
Earnings before income taxes . . . $ 	7,007 	$ 	841 	$ 	561 	$ 	832 	$ 	— $ 2,234 	$ 	(430) 	$ 	8,811
14

-- 16 of 30 --

Optum
(in millions) 	UnitedHealthcare OptumHealth OptumInsight OptumRx Optum
Eliminations Optum Corporate and
Eliminations Consolidated
Six Months Ended June 30, 2021
Revenues—unaffiliated
customers:
Premiums . . . . . . . . . . . . . . . $ 	105,416 	$ 	6,303 	$ 	— 	$ 	— 	$ 	— $ 6,303 	$ 	— 	$ 111,719
Products . . . . . . . . . . . . . . . . 	— 	17 	70 	16,686 	— 	16,773 	— 	16,773
Services . . . . . . . . . . . . . . . . 	4,790 	4,797 	1,891 	539 	— 	7,227 	— 	12,017
Total revenues—unaffiliated
customers . . . . . . . . . . . . . . . . . 	110,206 	11,117 	1,961 	17,225 	— 	30,303 	— 	140,509
Total revenues—affiliated
customers . . . . . . . . . . . . . . . . . 	— 	14,173 	3,742 	26,796 	(953) 	43,758 	(43,758) 	—
Investment and other income . . . . 	382 	413 	106 	107 	— 	626 	— 	1,008
Total revenues . . . . . . . . . . . . . . . $ 	110,588 	$ 	25,703 	$ 	5,809 	$ 44,128 	$ 	(953) $ 74,687 	$ (43,758) 	$ 141,517
Earnings from operations . . . . . . $ 	7,203 	$ 	2,090 	$ 	1,541 	$ 1,883 	$ 	— $ 5,514 	$ 	— 	$ 	12,717
Interest expense . . . . . . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(807) 	(807)
Earnings before income taxes . . . $ 	7,203 	$ 	2,090 	$ 	1,541 	$ 1,883 	$ 	— $ 5,514 	$ 	(807) 	$ 	11,910
Six Months Ended June 30, 2020
Revenues—unaffiliated
customers:
Premiums . . . . . . . . . . . . . . . $ 	95,632 	$ 	4,402 	$ 	— 	$ 	— 	$ 	— $ 4,402 	$ 	— 	$ 100,034
Products . . . . . . . . . . . . . . . . 	— 	16 	56 	16,606 	— 	16,678 	— 	16,678
Services . . . . . . . . . . . . . . . . 	4,173 	2,773 	1,655 	540 	— 	4,968 	— 	9,141
Total revenues—unaffiliated
customers . . . . . . . . . . . . . . . . . 	99,805 	7,191 	1,711 	17,146 	— 	26,048 	— 	125,853
Total revenues—affiliated
customers . . . . . . . . . . . . . . . . . 	— 	10,875 	3,385 	25,741 	(851) 	39,150 	(39,150) 	—
Investment and other income . . . . 	370 	265 	30 	41 	— 	336 	— 	706
Total revenues . . . . . . . . . . . . . . . $ 	100,175 	$ 	18,331 	$ 	5,126 	$ 42,928 	$ 	(851) $ 65,534 	$ 	(39,150) 	$ 126,559
Earnings from operations . . . . . . $ 	9,895 	$ 	1,553 	$ 	1,097 	$ 1,692 	$ 	— $ 4,342 	$ 	— 	$ 	14,237
Interest expense . . . . . . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(867) 	(867)
Earnings before income taxes . . . $ 	9,895 	$ 	1,553 	$ 	1,097 	$ 1,692 	$ 	— $ 4,342 	$ 	(867) 	$ 	13,370
15

-- 17 of 30 --

ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and
Notes and with our 2020 10-K, including the Consolidated Financial Statements and Notes in Part II, Item 8, “Financial
Statements” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” “we,” “our” or
“us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to
UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management’s Discussion and
Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic
conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and
uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking
statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2020 10-K
and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a diversified health care company with a mission to help people live healthier lives and help make the
health system work better for everyone. Our two complementary businesses—Optum and UnitedHealthcare—are driven by this
unified mission and vision to improve health care access, affordability, experiences and outcomes for the individuals and
organizations we are privileged to serve.
We have four reportable segments across our two business platforms, Optum and UnitedHealthcare:
• 	OptumHealth;
• 	OptumInsight;
• 	OptumRx; and
• 	UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement,
UnitedHealthcare Community & State and UnitedHealthcare Global.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in our 2020 10-K and additional information on our segments
can be found in this Item 2 and in Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I,
Item 1 of this report.
COVID-19 Trends and Uncertainties
The COVID-19 pandemic continues to evolve and the ultimate impact on our business, results of operations, financial condition
and cash flows remains uncertain. Overall care activity approached seasonal baselines, including a mix of temporary deferral of
care activity and COVID-19 related care costs. The temporary deferral of care was more than offset by COVID-19 related care
and testing costs, rebate requirements, and general economic impacts, such as impacts of unemployment. In future periods, care
patterns may moderately exceed normal baselines as previously deferred care is obtained and acuity temporarily rises due to
missed regular care. From time to time, health system capacity may be subject to possible increased volatility due to the
pandemic. Specific trends and uncertainties related to our two business platforms are as follows:
Optum. COVID-19 related care costs continued to impact our OptumHealth risk-based care delivery businesses, which were
partially offset by the continued temporary deferral of care. The temporary deferral of care reduced fee-for-service care delivery
16

-- 18 of 30 --

volume, as well as OptumInsight and OptumRx volume-based business activity, although we expect the impact to continue
decreasing as care returns to, and potentially exceeds, normal levels. We believe COVID-19 will continue to influence customer
and consumer behavior, both during and after the pandemic, which could impact how and where care is delivered and the
manner in which consumers wish to receive their prescription drugs or infusion services. We expect COVID-19 related care
costs and other economic impacts to be only partially offset by remaining temporary deferrals of care in the second half of the
year as health systems return to seasonally adjusted levels of care. As a result of the dynamic situation and broad-reaching
impact to the health system, the ultimate impact of COVID-19 on our Optum businesses is uncertain.
UnitedHealthcare. In 2021, we have continued expanded benefit coverage in areas such as COVID-19 related care and testing,
telemedicine, and pharmacy; continuing to assist our customers, care providers, members and communities in addressing the
COVID-19 crisis. UnitedHealthcare’s results of operations were negatively impacted by COVID-19 related care and testing,
rebate requirements and other revenue impacts and broader economic impacts, partially offset by the continued deferral of care.
Enrollment in our commercial products declined primarily due to employer actions in response to the pandemic, while the
increase in people served through Medicaid was attributable in part to continuing action by states to ease redetermination
requirements due to the COVID-19 public health emergency.
Increased consumer demand for care, potentially even higher acuity care, along with continued COVID-19 related care costs are
expected to result in increased future medical costs in the second half of the year. Disrupted care patterns, as a result of the
pandemic, have and may continue to temporarily affect the ability to obtain complete member health status information,
impacting revenue in businesses utilizing risk adjustment methodologies. The ultimate overall impact is uncertain and
dependent on the future pacing and intensity of the pandemic, the duration of policies and initiatives to address COVID-19, and
general economic uncertainty.
Business Trends
Our businesses participate in the United States, South American and certain other international health markets. Overall spending
on health care is impacted by inflation; utilization; medical technology and pharmaceutical advancement; regulatory
requirements; demographic trends in the population; and national interest in health and well-being. The rate of market growth
may be affected by a variety of factors, including macro-economic conditions, such as the impacts of COVID-19, and regulatory
changes, which could impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefit products, we start with our view of expected future costs, including any
potential impacts from COVID-19. We frequently evaluate and adjust our approach in each of the local markets we serve,
considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative
and regulatory considerations, including minimum medical loss ratio (MLR) thresholds and similar revenue adjustments. We
will continue seeking to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in both the small group and large group segments. We expect broad-
based competition to continue as the industry adapts to individual and employer needs amid reform changes.
Government programs in the community and senior sector tend to receive lower rates of increase than the commercial market
due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, health system utilization and
prescription drug costs. COVID-19 related care costs as well as the deferral of care have also impacted medical cost trends in
the current year and may continue in future years. Future medical cost trends may be impacted by increased consumer demand
for care, potentially even higher acuity care, due to the temporary deferral of care since the onset of the pandemic. We endeavor
to mitigate those increases by engaging physicians and consumers with information and helping them make clinically sound
choices, with the objective of helping them achieve high quality, affordable care. The continued uncertain impact of COVID-19
may impact our ability to estimate medical costs payable, which has resulted in, and could result in, increased variability to
medical cost reserve development.
17

-- 19 of 30 --

Regulatory Trends and Uncertainties
Following is a summary of management’s view of regulatory trends and uncertainties. For additional information regarding
regulatory trends and uncertainties, see Part I, Item 1 “Business—Government Regulation,” Part 1, Item 1A, “Risk Factors,”
Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 10-K.
Medicare Advantage Rates. Final 2022 Medicare Advantage rates resulted in an increase in industry base rates of
approximately 4.1%, short of the industry forward medical cost trend. We continue to manage costs through improving and
expanding our coordinated care models, value-based care arrangements and various consumer engagement tools.
Affordable Care Act (ACA) Tax. The Health Insurance Tax was permanently repealed by Congress, effective January 1, 2021.
The permanent repeal of the tax impacts year-over-year comparability of our financial statements, including revenues, operating
costs, medical care ratio (MCR), operating cost ratio, effective tax rate and cash flows from operations.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select second quarter 2021 year-over-year operating comparisons to second quarter 2020.
• 	Consolidated revenues grew 15%, UnitedHealthcare revenues grew 13% and Optum revenues grew 17%.
• 	UnitedHealthcare served 1.1 million more people domestically, driven by growth in community and senior programs,
partially offset a decrease in people served by our commercial business.
• 	Consolidated and UnitedHealthcare earnings from operations decreased due to lower temporary deferrals of care caused by
COVID-19, partially offset by an increase at Optum.
• 	Diluted earnings per common share were $4.46.
• 	Cash flows from operations for the six months ended June 30, 2021 were $11.5 billion.
• 	Return on equity was 25.2%.
18

-- 20 of 30 --

RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data)
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
2021 	2020 	2021 vs. 2020 	2021 	2020 	2021 vs. 2020
Revenues:
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 56,233 	$ 49,394 	$ 6,839 	14% $ 111,719 	$ 100,034 	$ 11,685 	12%
Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,433 	8,247 	186 	2 	16,773 	16,678 	95 	1
Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,099 	4,156 	1,943 	47 	12,017 	9,141 	2,876 	31
Investment and other income . . . . . . . . . . . . . . . 	556 	341 	215 	63 	1,008 	706 	302 	43
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	71,321 	62,138 	9,183 	15 	141,517 	126,559 	14,958 	12
Operating costs:
Medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . 	46,546 	34,678 	11,868 	34 	91,450 	75,678 	15,772 	21
Operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,359 	10,001 	358 	4 	20,582 	20,016 	566 	3
Cost of products sold . . . . . . . . . . . . . . . . . . . . . 	7,660 	7,501 	159 	2 	15,232 	15,188 	44 	—
Depreciation and amortization . . . . . . . . . . . . . . 	778 	717 	61 	9 	1,536 	1,440 	96 	7
Total operating costs . . . . . . . . . . . . . . . . . . . . . . . . . 	65,343 	52,897 	12,446 	24 	128,800 	112,322 	16,478 	15
Earnings from operations . . . . . . . . . . . . . . . . . . . . . . 	5,978 	9,241 	(3,263) 	(35) 	12,717 	14,237 	(1,520) 	(11)
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(410) 	(430) 	20 	(5) 	(807) 	(867) 	60 	(7)
Earnings before income taxes . . . . . . . . . . . . . . . . . . 	5,568 	8,811 	(3,243) 	(37) 	11,910 	13,370 	(1,460) 	(11)
Provision for income taxes . . . . . . . . . . . . . . . . . . . . . 	(1,196) 	(2,115) 	919 	(43) 	(2,560) 	(3,209) 	649 	(20)
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,372 	6,696 	(2,324) 	(35) 	9,350 	10,161 	(811) 	(8)
Earnings attributable to noncontrolling interests . . . . 	(106) 	(59) 	(47) 	80 	(222) 	(142) 	(80) 	56
Net earnings attributable to UnitedHealth Group
common shareholders . . . . . . . . . . . . . . . . . . . . . . . 	$ 4,266 	$ 6,637 	$ (2,371) 	(36)% $ 	9,128 	$ 10,019 	$ 	(891) 	(9)%
Diluted earnings per share attributable to
UnitedHealth Group common shareholders . . . . . . 	$ 	4.46 	$ 	6.91 	$ 	(2.45) 	(35)% $ 	9.55 	$ 	10.43 	$ 	(0.88) 	(8)%
Medical care ratio (a) . . . . . . . . . . . . . . . . . . . . . . . . . 	82.8% 	70.2% 	12.6% 	81.9% 	75.7% 	6.2%
Operating cost ratio . . . . . . . . . . . . . . . . . . . . . . . . . . 	14.5 	16.1 	(1.6) 	14.5 	15.8 	(1.3)
Operating margin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8.4 	14.9 	(6.5) 	9.0 	11.2 	(2.2)
Tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	21.5 	24.0 	(2.5) 	21.5 	24.0 	(2.5)
Net earnings margin (b) . . . . . . . . . . . . . . . . . . . . . . . 	6.0 	10.7 	(4.7) 	6.5 	7.9 	(1.4)
Return on equity (c) . . . . . . . . . . . . . . . . . . . . . . . . . . 	25.2% 	44.0% 	(18.8)% 	27.3% 	33.7% 	(6.4)%
(a) Medical care ratio is calculated as medical costs divided by premium revenue.
(b) Net earnings margin attributable to UnitedHealth Group shareholders.
(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity.
Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at
the end of each of the quarters in the year presented.
2021 RESULTS OF OPERATIONS COMPARED TO 2020 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenue
The increases in revenue were primarily driven by the increase in the number of individuals served through Medicare
Advantage and Medicaid; pricing trends; and organic and acquisition growth across the Optum business, primarily due to
expansion in care delivery and managed services. The increases partially offset a decrease in individuals served through our
commercial business due to the continued economic impacts of COVID-19.
19

-- 21 of 30 --

Medical Costs and MCR
Medical costs increased as a result of increased COVID-19 related care costs, lower temporary care deferrals, growth in people
served through Medicare Advantage and Medicaid and medical cost trends, partially offset by decreased people served in our
commercial business. The MCR increased due to increased COVID-19 related care costs and the decreased deferral of care over
the year ago quarter and the permanent repeal of the Health Insurance Tax. For the six months ended June 30, 2021, medical
costs and the MCR were also impacted by increased prior year favorable reserve development.
Operating Cost Ratio
The operating cost ratio decreased primarily due to the permanent repeal of the Health Insurance Tax, COVID-19 impacts on
revenue and operating costs in the prior year and operating efficiency gains, partially offset by business mix.
Income Tax Rate
Our effective tax rate decreased primarily due to the permanent repeal of the nondeductible Health Insurance Tax.
Reportable Segments
See Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more
information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including individuals
served by UnitedHealthcare by major market segment and funding arrangement, people served by OptumHealth and adjusted
scripts for OptumRx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also
allow management and investors to evaluate and understand business mix, customer penetration and pricing trends when
comparing the metrics to revenue by segment.
The following table presents a summary of the reportable segment financial information:
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
(in millions, except percentages) 	2021 	2020 	2021 vs. 2020 	2021 	2020 	2021 vs. 2020
Revenues
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 55,474 	$ 49,107 	$ 6,367 	13% $ 110,588 	$ 100,175 	$10,413 	10%
OptumHealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	13,300 	9,139 	4,161 	46 	25,703 	18,331 	7,372 	40
OptumInsight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,957 	2,632 	325 	12 	5,809 	5,126 	683 	13
OptumRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	22,524 	21,371 	1,153 	5 	44,128 	42,928 	1,200 	3
Optum eliminations . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(478) 	(447) 	(31) 	7 	(953) 	(851) 	(102) 	12
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	38,303 	32,695 	5,608 	17 	74,687 	65,534 	9,153 	14
Eliminations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(22,456) 	(19,664) 	(2,792) 	14 	(43,758) 	(39,150) 	(4,608) 	12
Consolidated revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 71,321 	$ 62,138 	$ 9,183 	15% $ 141,517 	$ 126,559 	$14,958 	12%
Earnings from operations
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 3,095 	$ 7,007 	$(3,912) (56)% $ 	7,203 	$ 	9,895 	$ (2,692) (27)%
OptumHealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,128 	841 	287 	34 	2,090 	1,553 	537 	35
OptumInsight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	762 	561 	201 	36 	1,541 	1,097 	444 	40
OptumRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	993 	832 	161 	19 	1,883 	1,692 	191 	11
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,883 	2,234 	649 	29 	5,514 	4,342 	1,172 	27
Consolidated earnings from operations . . . . . . . . . . . . . . . . 	$ 5,978 	$ 9,241 	$(3,263) (35)% $ 12,717 	$ 14,237 	$ (1,520) (11)%
Operating margin
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5.6% 	14.3% 	(8.7)% 	6.5% 	9.9% 	(3.4)%
OptumHealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8.5 	9.2 	(0.7) 	8.1 	8.5 	(0.4)
OptumInsight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	25.8 	21.3 	4.5 	26.5 	21.4 	5.1
OptumRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4.4 	3.9 	0.5 	4.3 	3.9 	0.4
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7.5 	6.8 	0.7 	7.4 	6.6 	0.8
Consolidated operating margin . . . . . . . . . . . . . . . . . . . . . . . 	8.4% 	14.9% 	(6.5)% 	9.0% 	11.2% 	(2.2)%
20

-- 22 of 30 --

UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
(in millions, except percentages) 	2021 	2020 	2021 vs. 2020 	2021 	2020 	2021 vs. 2020
UnitedHealthcare Employer & Individual . . . . . . . . . . . . . . . . . $ 14,942 $ 12,963 $ 1,979 	15% $ 29,574 $ 27,243 $ 2,331 	9%
UnitedHealthcare Medicare & Retirement . . . . . . . . . . . . . . . . . 	25,304 	22,855 	2,449 	11 	50,778 	46,007 	4,771 	10
UnitedHealthcare Community & State . . . . . . . . . . . . . . . . . . . . 	13,110 	11,523 	1,587 	14 	26,083 	22,976 	3,107 	14
UnitedHealthcare Global . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,118 	1,766 	352 	20 	4,153 	3,949 	204 	5
Total UnitedHealthcare revenues . . . . . . . . . . . . . . . . . . . . $ 55,474 $ 49,107 $ 6,367 	13% $ 110,588 $ 100,175 $ 10,413 	10%
The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major market
segment and funding arrangement:
June 30, Increase/
(Decrease)
(in thousands, except percentages) 	2021 	2020 	2021 vs. 2020
Commercial:
Risk-based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,840 	8,065 	(225) 	(3) %
Fee-based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	18,395 	18,705 	(310) 	(2)
Total commercial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26,235 	26,770 	(535) 	(2)
Medicare Advantage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,385 	5,605 	780 	14
Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,130 	6,210 	920 	15
Medicare Supplement (Standardized) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,390 	4,450 	(60) 	(1)
Total community and senior . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	17,905 	16,265 	1,640 	10
Total UnitedHealthcare—domestic medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	44,140 	43,035 	1,105 	3
Global . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,485 	5,365 	120 	2
Total UnitedHealthcare—medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	49,625 	48,400 	1,225 	3 %
Supplemental Data:
Medicare Part D stand-alone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,750 	4,120 	(370) 	(9) %
Commercial business decreased primarily due to increased unemployment. Medicare Advantage increased due to growth in
people served through individual and group Medicare Advantage plans. The increase in people served through Medicaid was
primarily driven by states continuing to ease redetermination requirements due to COVID-19, new state-based awards and
growth in people served through Dual Special Needs Plans.
UnitedHealthcare’s revenue increased due to growth in the number of individuals served through Medicare Advantage and
Medicaid and a greater mix of people with higher acuity needs, partially offset by a decrease in the number of individuals served
through commercial benefits, the permanent repeal of the Health Insurance Tax and the impacts of COVID-19 on risk adjusted
business. Earnings from operations for the three months ended June 30, 2021 decreased primarily due to the lower temporary
deferral of care. For the three and six months ended June 30, 2021, earnings from operations decreased due to COVID-19
related care costs, reduction in people served through commercial benefits and the impacts of COVID-19 on risk adjusted
business, partially offset by growth in people served through Medicare Advantage and Medicaid and the repeal of the Health
Insurance Tax.
21

-- 23 of 30 --

Optum
Total revenues and earnings from operations increased due to growth across the Optum businesses. The results by segment were
as follows:
OptumHealth
Revenue at OptumHealth increased primarily due to organic growth and acquisitions in care delivery and the impact of
COVID-19 at our fee-based businesses as consumers resumed elective care. Earnings from operations increased due to organic
growth and acquisitions and cost management initiatives. COVID-19 related care costs and temporary care deferrals affected
earnings from operations at our risk-based and fee-based businesses in offsetting manners. OptumHealth served approximately
99 million people as of June 30, 2021 compared to 97 million people as of June 30, 2020.
OptumInsight
Revenue at OptumInsight increased primarily due to growth in technology and managed services and increased activity levels in
our volume-based services as a result of care activity normalizing for payer and care provider clients. Earnings from operations
increased primarily due to productivity gains and cost management initiatives, as well as the factors impacting revenue.
OptumRx
Revenue and earnings from operations at OptumRx increased due to higher script volumes, pricing trends and organic growth in
pharmacy care services. Revenue for the six months ended June 30, 2021 also increased due to acquisitions. Earnings from
operations also increased as a result of continued supply chain management initiatives. OptumRx fulfilled 342 million and 316
million adjusted scripts in the second quarters of 2021 and 2020, respectively. The increase was due to the continued recovery
of script volumes from the second quarter of 2020 where volumes were negatively impacted by COVID-19, dispensing of
COVID-19 vaccines and organic growth.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
Six Months Ended
June 30, 	Increase/(Decrease)
(in millions) 	2021 	2020 	2021 vs. 2020
Sources of cash:
Cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 11,545 	$ 12,946 	$ (1,401)
Issuances of short-term borrowings and long-term debt, net of repayments . . . . . . . . . . . . . . . 	4,858 	5,215 	(357)
Proceeds from common stock issuances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	764 	870 	(106)
Customer funds administered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,395 	1,263 	1,132
Sales and maturities of investments, net of purchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	573 	(573)
Total sources of cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	19,562 	20,867
Uses of cash:
Common stock repurchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,900) 	(1,691) 	(1,209)
Cash paid for acquisitions, net of cash assumed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(4,642) 	(3,952) 	(690)
Purchases of investments, net of sales and maturities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,789) 	— 	(2,789)
Purchases of property, equipment and capitalized software . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,130) 	(920) 	(210)
Cash dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,548) 	(2,212) 	(336)
Purchases of redeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,338) 	— 	(1,338)
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,310) 	(607) 	(703)
Total uses of cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(16,657) 	(9,382)
Effect of exchange rate changes on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6 	(143) 	149
Net increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 2,911 	$ 11,342 	$ (8,431)
22

-- 24 of 30 --

2021 Cash Flows Compared to 2020 Cash Flows
Decreased cash flows provided by operating activities were primarily driven by decreased net earnings due to the lower
temporary deferral of care, the timing of prior year federal income tax payments and changes in working capital accounts. Other
significant changes in sources or uses of cash year-over-year included increased net purchases of investments, purchases of
redeemable noncontrolling interests and increased share repurchases, partially offset by increased customer funds administered.
Financial Condition
As of June 30, 2021, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $64.7 billion
included approximately $19.8 billion of cash and cash equivalents (of which $1.5 billion was available for general corporate
use), $42.1 billion of debt securities and $2.8 billion of investments in equity securities. Given the significant portion of our
portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to
have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-
average duration of 3.8 years and a weighted-average credit rating of “Double A” as of June 30, 2021. When multiple credit
ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average
credit rating.
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital
resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2020 was disclosed in Part II, Item 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 10-K. During the six
months ended June 30, 2021, there were no material changes to this previously disclosed information outside the ordinary
course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We
continually evaluate opportunities to expand our operations, including through internal development of new products, programs
and technology applications and acquisitions.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing
program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for
general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 8 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements” in our 2020 10-K.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to
debt-plus-shareholders’ equity ratio of not more than 60%. As of June 30, 2021, our debt to debt-plus-shareholders’ equity ratio,
as defined and calculated under the credit facilities, was approximately 39%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as, to
meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information
on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this
report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements” in our
2020 10-K.
Credit Ratings. Our credit ratings as of June 30, 2021 were as follows:
Moody’s 	S&P Global 	Fitch 	A.M. Best
Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook
Senior unsecured debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	A3 	Stable 	A+ 	Stable 	A 	Stable 	A- 	Positive
Commercial paper . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	P-2 	n/a 	A-1 	n/a 	F1 	n/a 	AMB-1 	n/a
23

-- 25 of 30 --

The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating
cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic
and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase
the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the six months ended June 30, 2021, we repurchased approximately 8 million shares at an
average price of $365.03 per share. As of June 30, 2021, we had Board authorization to purchase up to 50 million shares of our
common stock.
Dividends. In June 2021, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to
an annual rate of $5.80 compared to $5.00 per share. For more information on our dividend, see Note 6 of Notes to the
Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Pending Acquisitions. The Company has entered into agreements to purchase companies in the health care sector, most notably
Change Healthcare (NASDAQ: CHNG), subject to regulatory approvals and other customary closing conditions. The total
anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately $9 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial
Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7
in our 2020 10-K.
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated
Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates,
which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and
estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent
liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends.
On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results,
however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical
accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II,
Item 7 in our 2020 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the
Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in our 2020 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements
which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,”
“expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify
forward-looking statements. These statements may contain information about financial prospects, economic conditions and
trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending
on the outcome of certain factors including: risks associated with public health crises, large-scale medical emergencies and
pandemics, such as the COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or
changes in existing health care laws or regulations, or their enforcement or application; the DOJ’s legal action relating to the
risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue;
reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings
24

-- 26 of 30 --

program or the application of risk adjustment data validation audits; failure to maintain effective and efficient information
systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our
failure to comply with related regulations; risks and uncertainties associated with the pharmacy benefits management industry;
competitive pressures; changes in or challenges to our public sector contract awards; our ability to contract on competitive terms
with physicians, hospitals and other service providers; failure to attract, develop, retain, and manage the succession of key
employees and executives; the impact of potential changes in tax laws and regulations (including any increase in the U.S.
income tax rate applicable to corporations); failure to achieve targeted operating cost productivity improvements; increases in
costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully
our strategic alliances or complete or receive anticipated benefits of strategic transactions; fluctuations in foreign currency
exchange rates; downgrades in our credit ratings; our investment portfolio performance; impairment of our goodwill and
intangible assets; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund
our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or
continue repurchasing shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks
that may affect our business operations, financial condition and results of operations more fully in our filings with the SEC,
including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future
performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual
results may vary materially from expectations expressed or implied in this document or any of our prior communications. You
should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not
undertake to update or revise any forward-looking statements, except as required by law.
ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt
across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of
interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in
comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1%
point or 2% points as of June 30, 2021 on our investment income and interest expense per annum, and the fair value of our
investments and debt (in millions, except percentages):
June 30, 2021
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum (a)
Interest
Expense Per
Annum (a)
Fair Value of
Financial
Assets (b)
Fair Value of
Financial
Liabilities
2% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	472 	$ 	204 	$ 	(3,200) $ 	(8,864)
1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	236 	102 	(1,615) 	(4,831)
(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(88) 	(10) 	1,222 	5,640
(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(88) 	(10) 	1,555 	11,426
Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2021, the assumed hypothetical change
in interest rates does not reflect the full 100 and 200 basis point reduction in interest income or interest expense, as the rates are assumed not to fall below
zero. As of June 30, 2021 some of our investments had interest rates below 2% so the assumed hypothetical change in the fair value of investments does not
reflect the full 200 basis point reduction.
ITEM 4. 	CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in
reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time
periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
25

-- 27 of 30 --

In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the
participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our
disclosure controls and procedures as of June 30, 2021. Based upon that evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of
June 30, 2021.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed
Consolidated Financial Statements contained in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A,
“Risk Factors” of our 2020 10-K, which could materially affect our business, financial condition or future results. The risks
described in our 2020 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that
we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2020 10-K.
ITEM 2. 	UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates periodically. There
is no established expiration date for the program. During the second quarter 2021, we repurchased approximately 3 million
shares at an average price of $394.60 per share. As of June 30, 2021, we had Board authorization to purchase up to 50 million
shares of our common stock.
26

-- 28 of 30 --

ITEM 6. 	EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company
files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the
Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 	Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the
Company’s Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 	Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by
reference to Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on February 26,
2021)
4.1 	Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New
York (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3/A, SEC File
Number 333-66013, filed on January 11, 1999)
4.2 	Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between
UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the
Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)
4.3 	Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior
Indenture, dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated,
The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company’s
Quarterly Report on Form 10-Q for the quarter ended June 30, 2007)
4.4 	Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National
Association (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3, SEC
File Number 333-149031, filed on February 4, 2008)
31.1 	Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS 	XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL
tags are embedded within the Inline XBRL document.
101.SCH 	Inline XBRL Taxonomy Extension Schema Document.
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
* 	Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term
debt are not filed. The Company will furnish copies thereof to the SEC upon request.
27

-- 29 of 30 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/s/ 	ANDREW P. W ITTY 	Chief Executive Officer
(principal executive officer) Dated: 	August 3, 2021
Andrew P. Witty
/s/ 	J OHN F. REX
Executive Vice President and
Chief Financial Officer
(principal financial officer) Dated: 	August 3, 2021
John F. Rex
/s/ 	THOMAS E. ROOS
Senior Vice President and
Chief Accounting Officer
(principal accounting officer) Dated: 	August 3, 2021
Thomas E. Roos
28

-- 30 of 30 --